Centers for Disease Control and Prevention. Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. See http://www.guideline.gov/ (last accessed December 2008)
2.
TownsendCL, Cortina-BorjaM, PeckhamCS, de RuiterA, LyallH, TookeyPA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000–2006. AIDS2008;22:973–81
3.
WarszawskiJ, TubianaR, Le ChenadecJ, ; for ANRS French Perinatal Cohort. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French perinatal cohort. AIDS2008;22:289–99
4.
ClotetB, BellosN, MolinaJM, ; for POWER 1 and 2 study groups. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet2007;369:1169–78
5.
Department of Health and Human Services. AIDS info – HIV/AIDS Drug Information – Darunavir. See http://www.aidsinfo.nih.gov/DrugsNew
6.
GoldwirtL, ChhunS, ReyE, Quantification of darunavir (TMC114) in human plasma by high-performance liquid chromatography with ultra-violet detection. J Chromatogr B Analyt Technol Biomed Life Sci2007;857:327–31
7.
MarzoliniC, RudinC, DecosterdLA, Transplacental passage of protease inhibitors at delivery. AIDS2002;16:889–93
8.
GingelmaierA, KurowskiM, KästnerR, Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery. AIDS2006;20:1737–43
9.
StekAM, MirochnickM, CapparelliE, Reduced lopinavir exposure during pregnancy. AIDS2006;20:1931–9
10.
RipamontiD, CattaneoD, MaggioloF, Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS2007;21:2409–15
11.
BackD, SekarV, Hoetelmans RM. Darunavir: pharmacokinetics and drug interactions (Review). Antivir Ther2008;13:1–13
